Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Material research - 25/05/2020 Das Team der Yuri GmbH in Meckenbeuren

    Reaching up into weightlessness – a start-up that enables commercial research experiments in space

    Yuri, a start-up company founded in 2019 in the Lake Constance area, is aiming high. The company’s mission is to enable microgravity research into the development of materials, new medicines and vaccines, including research opportunities on the International Space Station (ISS). Yuri’s tailor-made solutions are faster and more affordable than previous space research missions.

    https://www.gesundheitsindustrie-bw.de/en/article/news/reaching-up-into-weightlessness-a-start-up-enables-commercial-research-experiments-in-space
  • Press release - 14/05/2020

    CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate

    CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
  • Press release - 13/05/2020

    Drug counterfeiters use fear of corona epidemic

    Falsified chloroquine tablets identified in Africa - University of Tübingen supports local pharmacists in the analysis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/arzneimittelfaelscher-nutzen-angst-vor-corona-epidemie
  • Prime Vector Technologies GmbH - 09/04/2020 Kleineres_Original_fuer_Kachel_Corona_AdobeStock_318040586_Kopie.jpg

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Press release - 08/04/2020

    New Alliance in the Fight Against Coronavirus and COVID-19

    Scientists from Heidelberg and Mannheim launch research and development task force

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
  • Press release - 16/03/2020

    CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide

    CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-focuses-on-the-development-of-mRNA-based-coronavirus-vaccine-to-protect-people-worldwide
  • Press release - 11/03/2020

    Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG

    CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that company founder and Chairman of the Supervisory Board Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer (CEO).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Company-Founder-Ingmar-Hoerr-Succeeds-Daniel-Menichella-as-CEO-of-CureVac-AG
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
  • Press release - 03/03/2020

    CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force

    Daniel Menichella, CEO of biopharmaceutical company CureVac, was today invited to the White House to discuss strategies and opportunities for the rapid development and production of a coronavirus vaccine with U.S. President Donald Trump, Vice President Mike Pence, members of the White House Coronavirus Task Force and high-ranking representatives of pharmaceutical and biotech companies working on the outbreak’s response.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavir
  • Article - 04/02/2020 Teaser_Meeresschnecke_biosyn.jpg

    Medicine from the blue blood of marine mollusks

    A “living pharmacy” crawls on the ocean floor off the coastline that stretches from Southern California to Mexico: biosyn Arzneimittel GmbH, a pharmaceutical company based in the city of Fellbach in southern Germany, produces a drug to treat bladder cancer, using the haemolymph, a vertebrate fluid equivalent to blood, of Megathura crenulata, commonly known as a giant keyhole limpet.

    https://www.gesundheitsindustrie-bw.de/en/article/news/medicine-from-blue-blood-marine-snails
  • Article - 18/11/2019 Messung_Immunantwort_Elispot2_Kopie.jpg

    Researchers successfully rejuvenate the immune system in animal models

    It is well known that stem cells age. Even the human immune system loses its power with age. Since all immune cells are derived from blood-forming stem cells, it is quite natural to associate the weakening of the immune system (immune senescence) with the ageing of blood-forming stem cells. Stem cell researchers and immunologists from the University of Ulm have now demonstrated the important role that blood-forming cells play in the ageing of the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/Researchers-successfully-rejuvenate-the-immune-system-in-animal-models
  • Expert interview on NTDs – part 3 - 24/09/2019 Curevac_Franz-Werner_Haas_.png

    Neglected tropical diseases – Franz-Werner Haas: the role of technology and pharmaceutical companies

    Neglected tropical diseases (NTDs) are poverty-related infectious diseases that suffer from scant attention in terms of research or control. NTDs exist in the shadow of the "big three": malaria, tuberculosis and HIV/AIDS. They affect many people living in poverty in the emerging and developing countries of the tropics and subtropics. Active control can only be achieved when people with NTDs are treated effectively and given information…

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-franz-werner-haas-die-rolle-von-technologie-und-pharmaunternehmen
  • Article - 11/06/2019 ZurHausen.jpg

    New pathogens in beef and cow's milk contributing to the risk of cancer

    A team of researchers led by Nobel laureate Prof. Dr. med. Dr. h.c. mult. Harald zur Hausen has discovered a new type of infectious agent in dairy and meat products produced from European cattle that increases the risk for colon and breast cancer. These so-called Bovine Meat and Milk Factors (BMMFs) are small DNA molecules that are similar in sequence to both bacterial plasmids and certain viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-pathogens-in-beef-and-cows-milk-contributing-to-the-risk-of-cancer
  • Expert interview on NTDs – part 1 - 11/04/2019 Carsten_Koehler_Profilbild_Tropenkrankheiten_Tuebingen.jpg

    Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

    More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-carsten-koehler-impulse-aus-baden-wuerttemberg
  • Article - 18/03/2019 European Union flag in the wind.

    EHR and PHR: digital records in the German healthcare system

    EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.

    https://www.gesundheitsindustrie-bw.de/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
  • Article - 05/03/2019 Schematic showing EBV particles in a blood vessel.

    Vaccination against oncogenic Epstein-Barr viruses

    Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
  • Plant breeding - 19/11/2018 Teaser_Nicotiana_tabacum_001.png

    Tobacco for health

    Plants can be used as biofactories to produce valuable active ingredients such as proteins, antibodies, dyes or vaccines. A project called Newcotiana aims to re-position the existent tobacco industry infrastructure. The project partners, including Prof. Dr. Holger Puchta from the Karlsruhe Institute of Technology, use modern breeding methods to develop tobacco varieties with new capabilities.

    https://www.gesundheitsindustrie-bw.de/en/article/news/tobacco-for-health
  • Expert interview - 17/10/2018 Porträtfoto von Dr. Ralf Schumacher

    Biologicals are becoming increasingly important to Boehringer Ingelheim

    Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
  • Cancer immunotherapy - 06/09/2018 Schematic showing the so-called breakthrough event as well as the expansion and invasion stages of cells during carcinogenesis.

    The immunogenicity of tumours and the development of new cancer medicines

    Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-immunogenicity-of-tumours-and-the-development-of-new-cancer-medicines
  • Article - 25/04/2018 Prevalence of malaria in Africa.

    Resistance, immunity and malaria vaccination

    People who have survived a malaria infection often develop immunity to the disease. International malaria research is aimed at exploiting a person's natural immunity in order to treat malaria effectively and avoid resistance to previously effective drugs. These new approaches also raise hopes that one day countries at high risk of malaria may be able to eradicate the devastating disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/resistance-immunity-and-malaria-vaccination
  • Article - 14/03/2018 Bild1_Prof.KnebelDoeberitz.jpg

    Patent versus publication: setting up start-ups in the sciences

    When it comes to universities as start-up incubators, the Massachusetts Institute of Technology (MIT) in the USA is often used as a prime example of entrepreneurial impact. Well over 100 high-tech spin-offs have been set up in the vicinity of the renowned university. Many German universities also offer attractive conditions for scientists with an entrepreneurial spirit.

    https://www.gesundheitsindustrie-bw.de/en/article/news/patent-versus-publication-setting-up-start-ups-in-the-sciences
  • Article - 20/02/2018 Anopheles mosquito biting the skin.

    New strategies against malaria

    Malaria, which is a mosquito-borne disease caused by Plasmodium parasites, is still one of the worst infectious human diseases. The parasites have developed resistance against previously effective drugs and new strategies to combat malaria are urgently needed.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-strategies-against-malaria
  • Press release - 13/02/2018

    CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria

    Extends ongoing collaboration with Bill & Melinda Gates Foundation with award of two new grants. CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the awarding of two new grants from the Bill & Melinda Gates Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-entwickelt-innovative-mrna-impfstoffe-gegen-influenza-und-malaria
  • Press release - 04/01/2018

    CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics

    CureVac AG, a leading clinical-stage biopharmaceutical company focused on the development of pioneering mRNA therapeutics, and Arcturus Therapeutics Ltd. (NASDAQ:ARCT), an RNA medicines company, today announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-arcturus-therapeutics-announce-broad-strategic-collaboration-to-advance-next-generation-of-lipid-mediated-mrna-thera
  • Press release - 30/10/2017 07777_de.jpg

    CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics

Page 3 / 9

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search